Arrhythmogenic right ventricular cardiomyopathy (ARVC) affects one in 5,000 people worldwide and has been a perennial puzzle for clinicians as to its cause and treatment. Now a cardiologist with the research team that has won Canada's prestigious Governor General's Innovation Award for identifying the gene responsible for the condition is looking to California for assistance in repairing it.

Mississauga, Ontario's Solaris Disinfection Inc. began developing its Lytbot core technology five years ago because of deficiencies it saw in other disinfection technologies at U.S. and Canadian hospitals. These include systems that use low pressure intensity mercury vapor that generates enough UV radiation to eliminate approximately 50 percent of the pathogens in hospital rooms. That's nowhere good enough, said Solaris COO Adam Steinhoff.